HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon-Reference-Cited by-同舟云学术

HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon

Published:2019-03-12 Issue:1 Volume:19 Page:
ISSN:1471-2334
Container-title:BMC Infectious Diseases
language:en
Short-container-title:BMC Infect Dis

Author:

Takou Desire,Fokam Joseph^ORCID,Teto Georges,Santoro Maria-Mercedes,Ceccherini-Silberstein Francesca,Nanfack Aubin Joseph,Sosso Samuel Martin,Dambaya Béatrice,Salpini Romina,Billong Serge Clotaire,Gori Caterina,Fokunang Charles Ntungwen,Cappelli Giulia,Colizzi Vittorio,Perno Carlo-Federico,Ndjolo Alexis

Funder

Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/content/pdf/10.1186/s12879-019-3871-0.pdf

Reference50 articles.

1. World Health Organization. HIV/AIDS: data and statistics. Geneva: World Health Organization; 2018 http://www.who.int/hiv/data/en/ , (Accessed on 09 January 2018).

2. World Health Organization. Global Health sector strategy on HIV, 2016–2021. Geneva: World Health Organization; 2017. http://www.who.int/hiv/strategy2016-2021/en/ , (Accessed on 09 January 2018).

3. World Health Organization. Progress report. Global action plan on HIV drug resistance 2017–2021. Geneva: World Health Organization; 2018. http://apps.who.int/iris/bitstream/handle/10665/255883/9789241512848-eng.pdf?sequence=1 .

4. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011 Oct;11(10):750–9. https://doi.org/10.1016/S1473-3099(11)70149-9 .

5. Günthard HF, Calvez V, Paredes R, et al. Human immunodeficiency virus drug resistance: 2018 recommendations of theInternational antiviral society-USA panel. Clin Infect Dis. 2018. https://doi.org/10.1093/cid/ciy463.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring disparities in HIV-1 pretreatment and acquired drug resistance in China from 2003 to 2022;Journal of Antimicrobial Chemotherapy;2024-07-24

2. SARS-CoV-2 genomic surveillance and reliability of PCR single point mutation assay (SNPsig® SARS-CoV-2 EscapePLEX CE) for the rapid detection of variants of concern in Cameroon;Heliyon;2024-04

3. “I feel drug resistance testing allowed us to make an informed decision”: qualitative insights on the role of HIV drug resistance mutation testing among children and pregnant women living with HIV in western Kenya;BMC Health Services Research;2023-08-24

4. Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens;Viruses;2023-08-02

5. Added Value of Next Generation Sequencing in Characterizing the Evolution of HIV-1 Drug Resistance in Kenyan Youth;Viruses;2023-06-22